SecBot SecBot
SECBOTREPLAY Home › Report › SGP

SGP · Q3 net loss $0.73/sh

SpyGlass Pharma, Inc. · PRESS-RELEASE filed Nov 11, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 4/10

PRESS-RELEASE filed Nov 11, 2026 at 16:05 ET

SpyGlass Pharma reported Q3 2026 net loss of $24.3M ($0.73 per share), wider than the $9.8M loss in Q3 2025, driven by higher R&D and G&A expenses. The company highlighted Phase 3 enrollment on track for its BIM-IOL System, four-year FIH efficacy data, and the acquisition of AVS for $13M. Cash of $215.8M is expected to fund operations through 2028.

  • Net loss of $24.3M ($0.73 per share) for Q3 2026 vs $9.8M ($4.53 per share) in Q3 2025
  • Cash, cash equivalents and short-term investments of $215.8M as of September 30, 2026
  • Acquired AVS for ~$13M in cash to secure commercial IOL manufacturing capacity
  • Phase 3 enrollment for BIM-IOL System on track, completion expected in 2027

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access